ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

ABBV-444is under clinical development by AbbVie and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye).

Jul 1, 2023 - 20:00

ABBV-444is under clinical development by AbbVie and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye).

Read the original article

Tags:

Previous Article

XKDCT-080 by Guangdong Xiankangda Biotechnology for Colorectal Cancer: Likelihoo...

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Metastatic Castration-Resis...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Breaking down House Speaker Mike Johnson’s health care plan

Breaking down House Speaker Mike Johnson’s health care ...

Oct 26, 2023

Here are the 10 drugs that will be up first for Medicare price negotiation

Here are the 10 drugs that will be up first for Medicar...

Aug 29, 2023

Galapagos enters deal to boost decentralised CAR-T therapy production

Galapagos enters deal to boost decentralised CAR-T ther...

May 19, 2024